On September 8, 2021, CHAI (Clinton Health Access Initiative Indonesia) held a webinar to discuss the Hepatitis C Virus market report.
This report provides market intelligence on hepatitis C (HCV) diagnosis and treatment in low- and middle-income countries to help guide the elimination of Hepatitis C.
On this occasion, Peduli Hati Bangsa, represented by Caroline Thomas as Director, was asked to provide insight and be a speaker in the webinar.
The topic that was raised as a presentation was the reduction in the price of DAA (Direct Acting Antivirus) in Indonesia.
Caroline and her team have been working to raise awareness about Hepatitis and HIV in Indonesia. In recent years, they have successfully advocated for the availability of affordable DAA in Indonesia. They have also played a role in the micro-elimination of Hepatitis C in 7 prisons and detention centers in Jakarta, Indonesia
Some of the important points summarized in Caroline’s presentation are:
- What is the process so that price reduction advocacy takes place?
- What tools or techniques are used in the advocacy?
- What are the main drivers behind changes in DAA prices in Indonesia?
- Is the price of DAA in Indonesia adequate?
- What impact will these changes have on the global elimination of HCV
- The importance of competition for the provision of DAA.
- Pricing and procurement transparency
More on CHAI at https://chaiindonesia.org/